Get to know PhalconBio, INCATE’s newest Stage II venture

Photo courtesy of Dr. Samuel Kilcher
In September, INCATE announced its latest Stage II recipient, PhalconBio GmbH, and shared how they are developing Dual-Action Phages to treat severe bacterial pneumonia.
While our press release shared the news, we didn’t want to overlook the details that make up so much of the entrepreneurial journey: the initial idea, the teamwork, the planning, the inspiration driving it all.
To learn more, we’re chatting with PhalconBio co-founder and general manager Dr. Samuel Kilcher. Read on as he shares more about the company’s origin story, his tips for other entrepreneurs, and what drives the team to make a difference against antimicrobial resistance.
Congratulations on your Stage II funding! Can you share the pitch you’d give someone who wasn’t familiar with PhalconBio?
PhalconBio is developing a precision medicine for severe bacterial lung infections in intensive-care patients. Our Dual-Action Phages (DAPs) are engineered bacteriophages — naturally occurring biological agents that specifically infect and kill bacteria — enhanced with a second antibacterial mechanism to increase their effectiveness.
PhalconBio’s lead program targets Pseudomonas aeruginosa in severe pulmonary infections, initially focusing on ventilator-associated pneumonia, with potential application across additional acute and chronic lung infections.
Tell us a bit about how PhalconBio got started.
The concept behind our Dual-Action Phage therapeutics originated during my time as a group leader at ETH Zurich, where we initially explored the technology for treating urinary tract infections. We later continued developing the platform at Micreos Pharmaceuticals, shifting our focus to Pseudomonas aeruginosa, a major cause of difficult-to-treat infections.
In 2024, an opportunity emerged to give the technology a dedicated and independent home, and PhalconBio was created. Since then we have focused on advancing our lead therapeutic program, while continuing to develop the broader potential of our engineered phage platform, including AI-based de novo protein design.
The elegance of Dual-Action Phages is that they turn the target bacterium into a local factory for additional antibacterial proteins. When the infected cell bursts, it releases both new phages and proteins. These proteins can attack neighboring bacteria through a different mechanism, extending the effect beyond the cells infected by the phage. We therefore combine two complementary antibacterial actions in a single therapeutic.
Can you tell us a bit about the PhalconBio core team? Where are you based?
We have a small core team dedicated to hands-on laboratory research and technology development. Much like a small team of software developers can build a platform with global reach, we believe a focused biotech team can achieve far more than its size suggests. In addition, over the past years, we have built a broad and deep ‘best-in-class’ partner network, comprising leaders in all relevant fields ranging from IP and Regulatory all the way to physicians and potential pharma licensees.
Thanks to this approach, we leverage our know-how, taking relevant insights on board early on rather than through long learning cycles.
Our labs are based in Wädenswil, on the shores of Lake Zurich. The view offers a free daily energy boost!
PhalconBio was selected as a Stage I INCATE venture. How did this partnership impact PhalconBio?
Being selected as a Stage I INCATE venture provided valuable independent validation of our technology and development strategy, while also increasing our visibility and strengthening our network across the antimicrobial resistance community, including clinicians, collaborators, investors, and potential pharmaceutical partners.
What does Stage II funding mean for PhalconBio?
The funding enables us to conduct one of the most important preclinical studies in our development program: evaluation of our lead candidate in a clinically relevant model of ventilator-associated pneumonia. The study is being developed together with IDIBAPS in Barcelona, one of Europe’s leading authorities on pneumonia and ventilator-associated pneumonia (groups of Dr. Laia Fernandez and Prof. Antoni Torres). Their involvement helps ensure that the study is designed around the clinical realities of treating VAP in the ICU and generates evidence that is relevant to subsequent clinical development.
The study will assess whether adding inhaled DAPs to standard-of-care antibiotics improves bacterial control, while evaluating delivery and tolerability. The findings will help guide further development and support discussions with pharmaceutical licensing partners.
So much of science is collaborative. Tell us a bit about the groups you work with.
PhalconBio works with leading scientific and clinical partners, including ETH Zurich, the University of Basel, Institut Pasteur, Loughborough University, and IDIBAPS Barcelona.
ETH Zurich Professors Alexander Harms and Martin Loessner advise us on phage biology and engineering. Through the NCCR AntiResist and our collaboration with Prof. Urs Jenal at the Biozentrum, University of Basel, we have access to clinical isolates and advanced lung tissue models to assess the efficacy and safety of our therapeutics. We have also conducted translational studies with Prof. Steffi Lehmann at the Zurich University of Applied Sciences, Prof. Nina Khanna at the University of Basel, and Prof. Laurent Debarbieux at the Institut Pasteur.
For formulation and delivery, we work with Prof. Danish Malik at Loughborough University. For our planned preclinical study, we are working with Dr Laia Fernández-Barat and Prof. Antoni Torres at IDIBAPS in Barcelona.
For our AI-driven de novo design of antibacterial effectors for the next generation of Dual-Action Phages, we work closely with Dr. Peter Braun and his team at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP.
These partnerships help us advance towards the clinic while continuing to innovate.
What advice do you have for other ventures looking to accelerate their innovations?
Start with strong proprietary expertise and a technology that brings a real meaningful advantage. Surround yourself with experienced people who want to help, but stay in charge of the core technology development. Above all, build a stable team of excellent people you can trust.
When it comes to funding, choose investors who share your long-term vision, understand the development journey and – ideally – can open doors through their network. Make the most of non-dilutive funding opportunities, too. Beyond financial support, these programs can offer access to expertise, greater visibility, and valuable external validation.
What motivates you to keep working in the field of AMR?
The work is challenging, but my motivation is simple: AMR is a global health threat that must be addressed. It is actually both a privilege and a responsibility to be part of the solution! But the perspective of thankful future patients and their families easily keeps us going!

